



PRESS RELEASE

## *MolMed and Megapharm enter into a license and distribution agreement for Zalmoxis® in Israel*

Milan (Italy), April 28, 2016 – MolMed S.p.A. (“MolMed”) and Megapharm Ltd (“Megapharm”) today announce they signed a distribution and license agreement which defines all terms and conditions for the supply, registration, promotion and distribution of Zalmoxis in Israel, as anticipated on December 1, 2016, when the companies signed a term sheet defining the main terms and conditions.

Zalmoxis is conditionally authorised by the European Commission for adult patients affected by leukaemia or other high-risk haematological malignancies, and is the first patient-specific cell therapy used in combination with haplo-identical haematopoietic stem cell transplant (haplo-HSCT).

Under the terms and conditions of today’s agreement Zalmoxis will be distributed and marketed by Megapharm, once approved by the Israeli Ministry of Health (MOH) and included in the Israeli National Health Basket of drugs by the MOH. Furthermore, Megapharm will be responsible for conducting all regulatory activities after marketing authorisation in Israel, including market access and price & reimbursement.

---

This press release is written in compliance with public disclosure obligations established by Consob’s (Italian securities & exchange commission) Issuers Regulation.

---

### **FROM GENES TO THERAPY**

#### **MOLMED S.p.A.**

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325

info@molmed.com - [www.molmed.com](http://www.molmed.com)

Share capital €20,312,682.30 fully paid - Office of Milan Company Registry number 1506630 –Tax identification number 11887610159



PRESS RELEASE

### *About MolMed*

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6 is an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP manufacturing of viral vectors and patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and an operating unit at OpenZone in Bresso (Milan, Italy). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

### *About Megapharm*

Megapharm Ltd. Is a leading Israeli private pharma marketing company, exclusively represents number of major American, European and Japanese pharmaceutical companies. Megapharm provides its partners with the full commercial capabilities, including registration, market access & reimbursement, sales & marketing, etc. Megapharm has demonstrated dynamic sales growth by developing a strong company presence and expertise in select therapeutic areas and proven track record for obtaining reimbursement and inclusion of its products in all the Health Funds in Israel.

### *For further information:*

#### *MolMed:*

**Laura Villa**

***Investor Relations & Communication Director***

phone: +39 02 21277.205

fax: +39 02 21277.325

e-mail: [investor.relations@molmed.com](mailto:investor.relations@molmed.com)

#### *Megapharm:*

**Ran Levin**

***Head of Business Development***

phone: +972 9 760 4596

fax: +972 9 7604514

e-mail: [info@megapharm.co.il](mailto:info@megapharm.co.il)

### **Press agent**

**Federico Ferrari**

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: [ferrari@segrp.it](mailto:ferrari@segrp.it)

### **DISCLAIMER**

*This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A..*

**FROM GENES TO THERAPY**